依西美坦与他莫昔芬联合卵巢抑制剂在绝经前乳腺癌治疗中的价值比较  

Exemestane and Tamoxifen Combined With Ovarian Inhibitors in the Treatment of Breast Cancer to Compare the Value of Premenopausal Women

作　　者：杨巧鹭[1] 张志明[1] 

机构地区：[1]厦门大学附属第一医院乳腺外科,361000

出　　处：《中国卫生标准管理》2015年第30期112-113,共2页China Health Standard Management

摘　　要：目的探讨依西美坦辅助卵巢抑制剂对绝经前乳腺癌的治疗效果。方法选择200例绝经前受体阳性乳腺癌患者,随机将其分为两组,对照组接受他莫昔芬治疗辅助卵巢抑制剂,实验组患者接受依西美坦辅助卵巢抑制剂治疗,分析临床治疗效果。结果实验组患者临床治疗效果优于对照组(P<0.05)。结论绝经前受体阳性乳腺癌患者接受依西美坦辅助卵巢抑制剂治疗,具有较高的临床效果。Objective To investigate the treatment effect of the exemestane assistant ovarian inhibitor on premenopausal breast cancer. Methods A total of 200 cases of premenopausal receptor-positive breast cancer patients were randomly divided into two groups. The control group received tamoxifen treatment assistant ovarian inhibitor and the experimental group received the exemestane assistant ovarian inhibitor treatment. Clinical treatment effects were analyzed. Results Patients in the experimental group had better clinical treatment effects than patients in the control group（P〈0.05）. Conclusion The exemestane assistant ovarian inhibitor for treatment had a relative high clinical effect for premenopausal receptor-positive breast cancer patients.

关 键 词：依西美坦 卵巢抑制剂 绝经前乳腺癌 治疗效果 

分 类 号：R737.9[医药卫生—肿瘤]